Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing

Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing

Abstract Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have the capacity to delay viral rebound when administered to people with HIV-1 (PWH) during anti-retroviral therapy (ART) interruption. To further enhance the performance of bNAbs through their Fc effec...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Steven W. de Taeye, Angela I. Schriek, Jeffrey C. Umotoy, Marloes Grobben, Judith A. Burger, Rogier W. Sanders, Gestur Vidarsson, Manfred Wuhrer, David Falck, Neeltje A. Kootstra, Marit J. van Gils
Natura:	Articolo
Lingua:	English
Pubblicazione:	Nature Portfolio 2024-08-01
Serie:	Communications Biology
Accesso online:	https://doi.org/10.1038/s42003-024-06659-8

Documenti analoghi

PP 8.8 – 00129 Antibody mediated killing of HIV-1 infected cells with glycoengineered broadly neutralizing antibodies
di: S. De Taeye, et al.
Pubblicazione: (2022-12-01)

A functional spleen contributes to afucosylated IgG in humans
di: Iwona Wojcik, et al.
Pubblicazione: (2021-12-01)

Acquisition of Fc-afucosylation of PfEMP1-specific IgG is age-dependent and associated with clinical protection against malaria
di: Mary Lopez-Perez, et al.
Pubblicazione: (2025-01-01)

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions
di: Angela I. Schriek, et al.
Pubblicazione: (2022-11-01)

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
di: Angela I. Schriek, et al.
Pubblicazione: (2022-05-01)

Afucosylated Plasmodium falciparum-specific IgG is induced by infection but not by subunit vaccination
di: Mads Delbo Larsen, et al.
Pubblicazione: (2021-10-01)

PP 8.5 – 00080 Fc-engineering of anti-HIV-1 antibodies and nanobodies to improve Fc mediated effector functions
di: A. Schriek, et al.
Pubblicazione: (2022-12-01)

Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells
di: Alexandros Karampatzakis, et al.
Pubblicazione: (2021-03-01)

Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression.
di: Marloes Grobben, et al.
Pubblicazione: (2024-12-01)

The Ligands for Human IgG and Their Effector Functions
di: Steven W. de Taeye, et al.
Pubblicazione: (2019-04-01)

MS-Based Allotype-Specific Analysis of Polyclonal IgG-Fc N-Glycosylation
di: Thomas Sénard, et al.
Pubblicazione: (2020-08-01)

Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses.
di: Karlijn van der Straten, et al.
Pubblicazione: (2024-08-01)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
di: Daniele Caracciolo, et al.
Pubblicazione: (2021-02-01)

Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure
di: Jeffrey C. Umotoy, et al.
Pubblicazione: (2021-07-01)

FcγR Binding and ADCC Activity of Human IgG Allotypes
di: Steven W. de Taeye, et al.
Pubblicazione: (2020-05-01)

Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry
di: Steffen Lippold, et al.
Pubblicazione: (2021-01-01)

Glycoform-resolved FcɣRIIIa affinity chromatography–mass spectrometry
di: Steffen Lippold, et al.
Pubblicazione: (2019-10-01)

Differences in IgG afucosylation between groups with and without carotid atherosclerosis
di: Cuihong Tian, et al.
Pubblicazione: (2024-11-01)

Kill and Clearance in HCC: An Approach Based on NK Cells and Macrophages
di: Maryam Mehrabi, et al.
Pubblicazione: (2021-09-01)

Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies
di: Myrthe E. Sonneveld, et al.
Pubblicazione: (2018-01-01)

Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody
di: Aaron Gupta, et al.
Pubblicazione: (2023-05-01)

Targeting Tn-positive tumors with an afucosylated recombinant anti-Tn IgG
di: Yasuyuki Matsumoto, et al.
Pubblicazione: (2023-03-01)

Affinity capillary electrophoresis – mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner
di: Christoph Gstöttner, et al.
Pubblicazione: (2022-09-01)

Understanding antibody-dependent enhancement in dengue: are afucosylated IgG1s a concern?
di: Teo, Andrew, et al.
Pubblicazione: (2023)

Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?
di: Andrew Teo, et al.
Pubblicazione: (2023-03-01)

Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?
di: Andrew Teo, et al.
Pubblicazione: (2023-03-01)

Enhancement of effector functions of anti-CD20 monoclonal antibody by increased afucosylation in CHO cell line through cell culture medium optimization
di: Bala Reddy Bheemareddy, et al.
Pubblicazione: (2022-10-01)

Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model
di: David Falck, et al.
Pubblicazione: (2022-12-01)

N-linked Fc glycosylation is not required for IgG-B-cell receptor function in a GC-derived B-cell line
di: Theresa Kissel, et al.
Pubblicazione: (2024-01-01)

Patients with IgG1-anti-red blood cell autoantibodies show aberrant Fc-glycosylation
di: Myrthe E. Sonneveld, et al.
Pubblicazione: (2017-08-01)

Assessment of the role of afucosylated glycoforms on the in vitro antibody-dependent phagocytosis activity of an antibody to Aβ aggregates
di: Allyson Kwiatkowski, et al.
Pubblicazione: (2020-01-01)

The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccineesResearch in context
di: Julie Van Coillie, et al.
Pubblicazione: (2023-01-01)

Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity
di: Grayson Hatfield, et al.
Pubblicazione: (2022-10-01)

Factors affecting IgG4-mediated complement activation
di: Nienke Oskam, et al.
Pubblicazione: (2023-01-01)

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia
di: Laurène Pousse, et al.
Pubblicazione: (2023-05-01)

Detection of Antibody-Dependent Cell-Mediated Cytotoxicity—Supporting Antibodies by NK-92-CD16A Cell Externalization of CD107a: Recognition of Antibody Afucosylation and Assay Optimization
di: Judith Cruz Amaya, et al.
Pubblicazione: (2023-06-01)

Trends in SPR Cytometry: Advances in Label-Free Detection of Cell Parameters
di: Richard B. M. Schasfoort, et al.
Pubblicazione: (2018-10-01)

Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV
di: Myrthe L. Verburgh, et al.
Pubblicazione: (2023-06-01)

Proteoform-Resolved FcɤRIIIa Binding Assay for Fab Glycosylated Monoclonal Antibodies Achieved by Affinity Chromatography Mass Spectrometry of Fc Moieties
di: Steffen Lippold, et al.
Pubblicazione: (2019-10-01)

Antibodies and their receptors: different potential roles in mucosal defence
di: Rachel eHorton, et al.
Pubblicazione: (2013-07-01)